To generate recommendations on the management of radiotherapeutic treatments during the pandemic, adapted to a country with limited health resources. We did a rapid review of the literature, searching for papers that describe any measures to reduce the risk of COVID-19 infection, as well as management guidelines to reduce the workload, in radiotherapy units.
Recently, increasing evidences indicated that Platycodin D (PD) served as an effective anti-tumor drug for cancer treatment in clinic. However, the molecular mechanisms are still unclear. In the present study, we proved that PD regulated LncRNA-XIST/miR-335 axis to hamper the development of bladder cancer in vitro and in vivo.
Bladder cancer (BCa) is among the ten most frequent cancers globally. It is the tumor with the highest lifetime treatment-associated costs, and among the tumors with the heaviest impacts on postoperative quality of life.
The prognosis and responsiveness to chemotherapy and checkpoint inhibitors differs substantially among patients with bladder cancer (BC). There is an unmet need for biomarkers that can accurately predict prognosis and treatment outcome.
Robotic-assisted radical cystectomy (RARC) has been gaining momentum as an alternative to its conventional open radical cystectomy (ORC) for the management of invasive bladder cancer. Although RARC, in general, demonstrated less blood loss and shorter hospital stay than ORC, whether there is any significant difference in the overall complication rate still requires further investigation.
Bladder cancer (BC) is the 9th most common cancer worldwide, but little progress has been made in improving patient outcomes over the last 25 years. The King’s Health Partners (KHP) BC biobank was established to study unanswered, clinically relevant BC research questions.
Alicia Morgans: Hi. My name is Alicia Morgans and I am a GU medical oncologist and an associate professor of medicine at Northwestern University in Chicago in the United States. I’m so excited to have here with me today, Dr. Ben Tran, who is a consultant GU medical oncologist in Melbourne Australia, where he is […]
Alicia Morgans: Hi, my name is Alicia Morgans. I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University. I am so excited to have here with me today, a friend and good colleague. Dr. Josh Meeks, who is a urologist here at Northwestern, as well as being an assistant professor of urology has […]
Ashish Kamat: Hello, and welcome to UroToday’s Bladder Cancer Center of Excellence. I’m Ashish Kamat from Houston at MD Anderson Cancer Center. It’s a pleasure to be joined today by Dr. Van der Heijden from the Netherlands Cancer Institute. We’ve been discussing in the social media circles and in person before obviously, COVID hit, the […]
Relugolix had a similar rate of castration resistance-free survival in the subgroup of men with metastatic disease compared to leuprolide acetate (74% vs. 75%, respectively) and did not achieve statistical superiority (p = 0.84) Relugolix is under Priority Review with an FDA target action date of December 20, 2020, supported by positive Phase 3 HERO study results including a 97% responder rate and six positive key secondary endpoints San Francisco, CA (UroToday.com) — Myovant Sciences, a healthcare company focused […]
